Survey of strength training habits in adults taking GLP-1 medications
Surveys adults taking GLP-1 medications about their resistance training before and after starting.
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 12 Jun 2026
- Expected to end
- Jan 2027
- Type of study
- Observational
- Treatments tested
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Record updated
- 24 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who take a GLP-1 medicine for type 2 diabetes or weight control. They fill in one anonymous online survey of about 10 minutes about strength training.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Taking a GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and/or weight management (self-reported).
- Earlier treatment
- Must have taken a GLP-1 receptor agonist for at least 3 months, at a stable dose for the past 4 to 8 weeks.
Main reasons for not taking part
- Currently pregnant or planning to become pregnant
- Planned bariatric surgery within the next 3 months
- Bariatric surgery within the past 3 months
- Other conditions that greatly change the ability to do resistance training, for example advanced cancer cachexia or severe conditions limiting movement
- Cannot read or answer the survey in English
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adult aged 18 years or older
- Currently taking a GLP-1 receptor agonist medication
- On the GLP-1 receptor agonist for at least 3 months
- Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and/or weight management (self-reported)
- Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks
- Able to read and respond to the survey in English
- Willing and able to provide informed consent electronically
Who cannot take part
- Planned bariatric surgery within the next 3 months
- Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions)
- Currently or planning to become pregnant
- Unable to read or respond to the survey in English
Where in United States
- The Ohio State UniversityColumbus, United StatesContact: Madison L Kackley, PhDTaking people
About the trial
What the trial wants to find out
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength) training before and after starting their medication.
Read full original descriptionShow less
GLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Losing muscle can make it harder to move, do everyday tasks, and stay strong as we age. Resistance training, things like lifting weights, using resistance bands, or doing push-ups and squats, is the most effective way to keep and build muscle. Yet most adults in the United States do not meet the recommended amount of resistance training, and very little is known about the resistance training habits of people who take GLP-1 medications.
The purpose of this research is to systematically collect information from adults using GLP-1 medications so we can better understand: how often they do resistance training before and after starting the medication; what their sessions look like (frequency, duration, intensity, muscle groups); whether their resistance training is linked to how strong they feel and how well they can carry out daily activities; and what makes resistance training easier or harder while on a GLP-1 medication.
Findings will help doctors, dietitians, exercise professionals, and researchers design better guidance and interventions to protect muscle mass, physical function, and quality of life in people using GLP-1 medications.
Who can join: Adults 18 years or older who are currently taking a GLP-1 receptor agonist medication for type 2 diabetes, overweight or obesity, or weight management, and who have been on the medication for at least three months at a stable dose. Participants must be able to read and respond to the survey in English. People who are pregnant or planning bariatric surgery within the next three months are not eligible.
What participants will do: The study is a single, anonymous, online survey. Interested individuals click the survey link, review a short consent page, and indicate their willingness to participate. Eligible participants then answer questions about their background, current health, GLP-1 medication and dose, resistance training habits before and after starting the medication, self-reported strength and function, and things that make resistance training easier or harder. There are no in-person visits, no exercise tests, and no blood draws.
How long it takes: About 10 minutes total, in one online session. There is no follow-up after the survey and no compensation is offered.
Data privacy: The survey is anonymous. No names, email addresses, or IP addresses are collected or linked to responses. The survey runs on Qualtrics, a secure, institution-approved platform hosted on Ohio State University servers.
The research team hopes to enroll up to 200-300 adults across the United States.
Treatments tested
- Glucagon-Like Peptide-1 Agonist (GLP-1)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
- Plain-language title
- Survey of strength training habits in adults taking GLP-1 medicationsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 24 July 2026